Tom Cupedo

Erasmus MC — Netherlands

Immunology and Microbiology · Life Sciences

42h-index8.4kcitations187works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(45), Immune cells in cancer(39), Multiple Myeloma Research and Treatments(35), IL-33, ST2, and ILC Pathways(34), T-cell and B-cell Immunology(31)

Publications186 total

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load
Blood·2025· 1 citedOpen Access
Table S1 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
2025Open Access
Table S2 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
2025Open Access
Table S6 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
2025Open Access
Table S5 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
2025Open Access
Table S3 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
2025Open Access
Table S7 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
2025Open Access
Table S4 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
2025Open Access
Supplementary Figure 1-9 from A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML
2025Open Access
Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.
Blood·2025Open Access
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone
Blood·2025· 4 citedOpen Access
European Myeloma Network Group Consensus Statement on the use of next‐generation sequencing for prognostic stratification of newly diagnosed multiple myeloma
HemaSphere·2025· 2 citedOpen Access
Syntenin inhibition impairs stroma‐tumor communication in multiple myeloma and improves bortezomib treatment efficiency
HemaSphere·2025· 2 citedOpen Access
Cytolytic helper T cells: a new addition to myeloma immunity
Blood·2025Open Access
The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy
Blood·2025· 9 citedOpen Access
Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myeloma
Blood·2025· 8 citedOpen Access
Interferon gamma‐mediated prevention of tumor progression in a mouse model of multiple myeloma
HemaSphere·2024· 3 citedOpen Access
Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study
Blood·2024· 2 cited
Table S1 from A SINGLE-CELL TAXONOMY PREDICTS INFLAMMATORY NICHE REMODELING TO DRIVE TISSUE FAILURE AND OUTCOME IN HUMAN AML
2024Open Access
Table S3 from A SINGLE-CELL TAXONOMY PREDICTS INFLAMMATORY NICHE REMODELING TO DRIVE TISSUE FAILURE AND OUTCOME IN HUMAN AML
2024Open Access
page 1 of 10Next →

Frequent Co-authors

Natalie Papazian(15), Reina E. Mebius(11), Hergen Spits(10), Mark Coles(8), Remco M. Hoogenboezem(7), Mónica Romera‐Hernández(5), Mathijs A. Sanders(5), Ferry Cornelissen(5), Georg Kraal(5), Kees Weijer(4), Patricia Aparicio‐Domingo(4), Julien J. Karrich(4), Janneke N. Samsom(4), Kerim Hoorweg(4), Burkhard Ludewig(4), Natasha K. Crellin(3), Madelon M.E. de Jong(3), P.K. Bos(3), Philippe Moreau(3), Mark van Duin(3)